Oral soft gel capsule containing psychedelic compound

A method of treating anxiety in a subject, the method comprising orally administering to a subject in need or at risk thereof an oral soft gel capsule comprising:

• (i) a capsule shell formed from gelatin and at least one of vegetable starch, tapioca starch, carrageenan, potato starch, cassava starch, cornstarch, and arrowroot;
• (ii) a psychedelic compound comprising at least one of psilocybin, psilocin, and baeocystin;
• and
• (iii) liquid vehicle comprising at least one of glycerin, beeswax, tocopherols, polyoxyethylene-polyoxypropylene copolymers, and Caprylic/Capric Triglyceride;
• wherein,
• the psilocybin, psilocin baeocystin, or combination thereof is present in a combined amount of 0.01 to 5 mg,
• the psilocybin, psilocin, baeocystin, or combination thereof has a purity of at least 99 wt. % pure,
• the psilocybin, psilocin, baeocystin, or combination thereof is obtained from the genera Copelandia, Gymnopilus, Inocybe, Mycena, Panaeolus, Pholiotina, Pluteus, or Psilocybe,
• the liquid vehicle is compatible with the capsule shell;
• the liquid vehicle effectively dissolves and/or suspends the psychedelic compound;
• and
• the psychedelic compound and the liquid vehicle are contained within the capsule shell.